Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients

References

• Ministry of Health Labour Welfare of Japan2005 Nanchisei shikkan kokufuku kenkyu jigyou moumyakurakumaku/shishinkei ishukushou ni taisuru kenkyu Heisei 17nendo soukatsu/buntan kenkyu houkokusho [Report of the Research Committee on Chorioretinal Degenerations and Optic Atrophy]2006263267 Japanese
   Google Scholar
• RosenfieldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfieldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol2007143456658317386270
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
   PubMed Web of Science ®Google Scholar
• HolzFGAmoakuWDonateJSUSTAIN Study GroupSafety and efficacy of a fexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN studyOphthalmology2011118466367121459217
   PubMed Web of Science ®Google Scholar
• GuptaOPShienbaumGPatelAHFecarottaCKaiserRSRegilloCDA treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impactOphthalmology2010117112134214020591490
   PubMed Web of Science ®Google Scholar
• OubrahamHCohenSYSamimiSInject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degenerationRetina2011311263020890246
   PubMed Web of Science ®Google Scholar
• ShoKTakahashiKYamadaHPolypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristicsArch Ophthalmol2003121101392139614557174
   PubMedGoogle Scholar
• ObataRYanagiYKamiJTakahashiHInoueYTamakiYPolypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degenerationJpn J Ophthlmol2006504354360
   Web of Science ®Google Scholar
• MarukoIIidaTSaitoMNagayamaDSaitoKClinical characteristics of exudative age-related macular degeneration in Japanese patientsAm J Ophthalmol20071441152217509509
   PubMed Web of Science ®Google Scholar
• GomiFSawaMSakaguchiHEfficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathyBr J Ophthalmol2008921707317567661
   PubMed Web of Science ®Google Scholar
• YannuzziLAWongDWSforzoliniBSPolypoidal choroidal vasculopathy and neovascularized age-related macular degenerationArch Ophthalmol1999117111503151010565519
   PubMedGoogle Scholar
• SuzukiMGomiFSawaMTsujikawaMSakaguchiHBevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patientsJpn J Ophthalmol201054212412820401560
   PubMed Web of Science ®Google Scholar
• TsujikawaAOotoSYamashiroKTamuraHOtaniAYoshimuraNTreatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumabJpn J Ophthalmol201054431031920700799
   PubMed Web of Science ®Google Scholar
• TanoYOhjiMEXTEND-I Study GroupEXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degenerationActa Ophthalmol201088330931620163368
   PubMed Web of Science ®Google Scholar
• MatsumiyaWHondaSBesshoHKusuharaSTsukaharaYNegiAEarly responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathyJ Ophthalmol2011742020
   Google Scholar
• Japanese Study Group of Polypoidal Choroidal VasculopathyCriteria for diagnosis of polypoidal choroidal vasculopathyNippon Ganka Gakkai Zasshi20051097417427 Japanese16050460
   PubMedGoogle Scholar
• YannuzziLANegrãoSIidaTRetinal angiomatous proliferation in age-related macular degenerationRetina200121541643411642370
   PubMed Web of Science ®Google Scholar
• HikichiTHiguchiMMatsushitaTOne-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patientsAm J Ophthalmol2012154111712422465366
   PubMed Web of Science ®Google Scholar
• KimKSLeeWKBevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathyJpn J Ophthalmol201155437037721647565
   PubMed Web of Science ®Google Scholar
• WakabayashiTGomiFSawaMTsujikawaMNishidaKIntravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathyBr J Ophthalmol201296339439921719568
   PubMed Web of Science ®Google Scholar
• ChoHJKimJWLeeDWChoSWKimCGIntravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathyEye (Lond)201226342643322173075
   PubMed Web of Science ®Google Scholar
• SongMHRyuHWRohYJOne-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathyOphthalmologica2011226311912621757883
   PubMed Web of Science ®Google Scholar
• KohALeeWKChenLJEVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathyRetina20123281453146422426346
   PubMed Web of Science ®Google Scholar
• Reche-FrutosJCalvo-GonzalezCPérez-TrigoSFernandez-PerezCDonate-LopezJGarcia FeijooJRanibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcomeEur J Ophthalmol201121678378821484755
   PubMed Web of Science ®Google Scholar
• LeeMYKimKSLeeWKCombination therapy of ranibizumab and photodynamic therapy for retinal angiomatous proliferation with serous pigment epithelial detachment in Korean patients: twelve-month resultsRetina2011311657321187732
   PubMed Web of Science ®Google Scholar
• SaitoMIidaTKanoMCombined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferationAm J Ophthalmol2012153350451422078902
   PubMed Web of Science ®Google Scholar